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Abbreviations:  
Ang1, angiopoietin 1;  
DMSO, dimethyl sulfoxide;  
EBM, endothelial basal medium;  
FBS, fetal bovine serum;  
FGF, fibroblast growth factor;  
HIF, hypoxia inducible factor;  
HUVECs, human umbilical vein endothelial cells;  
MDR, multidrug resistance. 
MRP 1, multidrug resistance associated protein 1;  
PlGF, placental growth factor;  
siRNA, small interfering RNA;  
TBS, Tris-buffered saline;  
VEGF, vascular endothelial growth factor;  
VEGFR, VEGF receptor;  
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Abstract 
Signal transduction pathways leading to angiopoietin 1 (Ang1)-induced capillary 
morphogenesis by endothelial cells remain poorly defined. Angiogenic cellular responses by 
endothelial cells may be modulated in vivo by chronic hypoxia, such as that induced by tumors. 
Here, we studied Ang1-induced capillary morphogenesis in human umbilical-vein endothelial 
cells (HUVECs) cultured chronically under normoxic (21% oxygen) or hypoxic (1.5% 
oxygen) conditions. Downregulation of Src using a small interfering RNA (siRNA) inhibited 
Ang1-induced capillary morphogenesis of HUVECs cultured under both conditions by 
blocking cell spreading and protrusion. Ang1 upregulated the Src-dependent secretion of 
vascular endothelial growth factor-A (VEGF-A). Blockade of endogenous VEGF-A also 
inhibited Ang1-induced capillary morphogenesis. Addition of exogenous VEGF-A restored 
cell spreading and protrusion, leading to Ang1-induced capillary morphogenesis of Src 
siRNA-treated HUVECs, suggesting that Ang1-induced VEGF-A secretion through Src was 
required for capillary morphogenesis. PP2 inhibited both Ang1-induced capillary 
morphogenesis and Src activation in HUVECs cultured under normoxic conditions, but the 
PP2 activity was significantly impaired in HUVECs cultured under hypoxic conditions. 
Expression of multidrug resistance-associated protein 1 (MRP 1) was upregulated in hypoxic 
HUVECs, and treatment with MRP 1 siRNA restored the inhibitory action of PP2. Taken 
together, our results suggest that Ang1 induces capillary morphogenesis in HUVECs through 
Src-dependent upregulation of endogenous VEGF-A. Conditions of chronic hypoxia impaired 
the effect of PP2, possibly via MRP 1. 
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1. Introduction 
 
Angiopoietins and their specific receptor tyrosine kinase, Tie 2, are implicated in the regulation 
of vascular and lymphatic vessel development and pathophysiological angiogenesis. 
Angiopoietin 1 (Ang1) positively stimulates angiogenesis in certain tumors [1-4], inducing 
proliferation, migration and survival of endothelial cells [5-7]. Thus, Tie 2 signaling represents 
a potential target for the treatment of advanced cancers in human. Cellular responses in 
Ang1-treated endothelial cells are largely regulated through the Ras/mitogen-activated protein 
kinase and phosphoinositide 3-kinase/Akt pathways [5,6]. However, the role of Src family 
kinases in Ang1-induced cellular responses of endothelial cells has not yet been determined. 
 The Src family of protein tyrosine kinases plays a role in tumor progression and 
angiogenesis [8,9]. Src family kinases have been linked to angiogenic cellular responses of 
endothelial cells as well as in vivo angiogenesis promoted by fibroblast growth factor-2 
(FGF-2), Ang2, vascular endothelial growth factor-A (VEGF-A), and hepatocyte growth factor 
[10-21]. Recently, anti-VEGF receptor-2 (VEGFR-2) blocking antibody inhibited 
angiogenesis and initial tumor growth in a mouse pancreatic islet tumor model. However, 
VEGFR-2 blockade alone failed to inhibit late-stage tumor growth, which was driven by 
FGF-2-induced angiogenesis [22]. This result suggested that blocking VEGF alone may induce 
VEGF-resistant angiogenesis and that the simultaneous inhibition of signal transduction 
pathways driven through multiple proangiogenic factor receptors may be required for complete 
inhibition of angiogenesis. Synthetic small-molecule protein kinase inhibitors, such as Src 
inhibitor PP2, may thus have the potential to block angiogenesis in advanced human cancers.  
 Many preclinical studies have used transplanted xenograft tumor models to assess the 
efficacy of antiangiogenic molecules. In these models in which tumor cells rapidly induce 
angiogenesis to evade host-tissue hypoxia, antiangiogenic therapies potently influence the 
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tumor growth by inhibiting angiogenesis. However, in clinical trials of patients with malignant 
tumors, antiangiogenic monotherapy had little effect on tumor regression or on prolongation of 
patient survival. Human tumors grow slower than xenograft tumors, resulting in longer 
exposure of the endothelial cells to hypoxic conditions. The different characteristics of 
angiogenesis in transplanted tumors and autochthonous tumors may therefore reflect different 
sensitivities of the endothelial cells to synthetic protein kinase inhibitors as a function of 
oxygen tension. Assessments of these inhibitors with respect to angiogenesis have initially 
been conducted using cultured endothelial cells. Under normoxic conditions (usually 21% 
oxygen in air), the oxygen tension of the culture medium is approximately 160 mmHg [23]. 
Oxygen tension in normal human end-capillary blood is 45–50 mmHg, whereas that in hypoxic 
tumor tissue is 8–10 mmHg [24]. Thus, it is possible that the sensitivity of endothelial cells to 
synthetic small-molecule protein kinase inhibitors may differ under normoxic and hypoxic 
(1.5–2.0% O2) conditions. 
 The present study was designed to determine the role of Src in the signal transduction 
pathways leading to Ang1-induced capillary morphogenesis in both normoxia and hypoxia. 
The results showed that the sensitivity of Ang1-induced capillary morphogenesis to a Src 
family kinase inhibitor, PP2, was attenuated in endothelial cells cultured under chronic 
hypoxic conditions, possibly via upregulation of multidrug resistance-associated protein 1 
(MRP 1).  
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2. Materials and methods 
 
2.1 Materials  
 
Anti-Src polyclonal antibodies (N-16 for immunoprecipitation and SRC2 for 
immunoblotting), anti-Tie 2 antibody, anti-phosphotyrosine monoclonal antibody (PY-99), 
anti-MRP 1 antibody, non-targeting control small interfering RNAs (siRNA), and MRP 1 
siRNA (sequences not available) were purchased from Santa Cruz Biotechnologies (Santa 
Cruz, CA). Histidine-tagged recombinant human Ang1, monoclonal anti-polyhistidine 
monoclonal antibody for cross-linking of histidine-tagged proteins, recombinant human 
VEGF-A, recombinant human placental growth factor 1 (PlGF-1), recombinant mouse 
VEGF-A, and the Quantikine® human VEGF-A ELISA kit were obtained from R & D Systems 
(Minneapolis, MN). Growth factor-reduced Matrigel matrix and anti-hypoxia inducible 
factor-1 (HIF-1) antibody were purchased from BD Bioscience (Bedford, MA). Anti-pY418 
Src antibody was obtained from BioSource International (Camarillo, CA), and anti-vinculin 
monoclonal antibody (hVIN-1) was from Sigma-Aldrich (St. Louis, MO). HiPerFect® 
transfection reagent and human Src siRNA (Hs_SRC_5_HP Validated siRNA, assessed by 
immunoblotting, sequence not available) were purchased from Qiagen (Tokyo, Japan). A 
pyrrolopyrimidine-derivative of Src inhibitor, PP2, was obtained from Merck (Tokyo); it was 
dissolved in dimethyl sulfoxide (DMSO) and stored at -20°C until use. For experiments, the 
stock solution was further diluted with DMSO if required and dissolved in culture medium. 
The final concentration of DMSO in the culture medium was always 0.1% (V/V). Verapamil 
was obtained from Wako Pure Chemicals (Osaka, Japan), and was dissolved in water 
immediately before use. 
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2.2 Cell culture 
 
Human umbilical vein-derived endothelial cells (HUVECs) and the appropriate 
culture medium were obtained from Cambrex (Walkersville, MD). HUVECs were cultured in 
endothelial basal medium (EBM)-2 supplemented with 2% fetal bovine serum (FBS), 20 ng/ml 
FGF-2, 20 ng/ml VEGF-A, 10 ng/ml epidermal growth factor, 20 ng/ml insulin-like growth 
factor-I, and 1 g/ml hydrocortisone. Cells were cultured in an atmosphere of either a mixture 
of 95% air and 5% CO2 (normoxic condition; 21% O2), or 93.5% N2, 5% CO2, and 1.5% O2 
(hypoxic condition). O2 tension was monitored using an O2 Monitor, type MB1000 (CHINO 
Corporation, Tokyo). HUVECs were cultured under these conditions for at least 7 days before 
use. For the hypoxic culture, fresh culture medium was pre-incubated in the hypoxic 
atmosphere for overnight before use.  
 
2.3 Transfection of siRNA  
 
HUVECs were transfected with the indicated siRNA using HiPerFect reagent. 
After 2 days, cells were detached from the wells and submitted to a capillary morphogenesis 
assay. Four thousand cells from each treatment were lysed and expression of Src and MRP 1 
was examined by immunoblotting. 
 
2.4 Capillary morphogenesis assay  
 
The capillary morphogenesis assay was carried out as described previously [25]. 
In brief, HUVECs suspended in culture medium containing 0.5% FBS were inoculated onto 
growth factor-reduced Matrigel, with or without treatment, and cultured for 24 h. To quantify 
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the length of capillaries, three different phase-contrast photomicrographic images (x 4 
objective) per well were taken, and the length of each capillary was measured using NIH image 
analysis software (version 1.64). Capillary length for cells without any treatment was set to 1.0. 
Values are expressed as means ± SD of three images. To examine the kinetics of capillary 
morphogenesis, cells seeded onto Matrigel were serially photographed at indicated periods. 
 
2.5 Immunoblot analyses  
 
Two sets of cultures in 24-well plates were prepared; one set was used for 
immunoblotting and the other set for cell counts. Alternatively, siRNA-transfected cells were 
centrifuged and pelleted. Cells were lysed by boiled SDS-sample buffer, and the proteins from 
equal numbers of cells were separated on SDS-polyacrylamide gels. Proteins were 
electrotransferred onto polyvinylidene difluoride membranes. Membranes were incubated with 
the indicated antibodies, followed by incubation with peroxidase-conjugated secondary 
antibodies. Proteins were visualized by enhanced chemiluminescence reaction (Pierce 
Biotechnology, Rockford, IL) and exposure on X-ray film. To assess the tyrosine 
phosphorylation of Src and Tie 2, HUVECs cultured under either normoxic or hypoxic 
conditions were serum-starved for 2 h and then stimulated or left unstimulated with Ang1 for 8 
min. Cells were washed with Tris-buffered saline, lysed in lysis buffer [7], and tyrosine 
phosphorylation of Src or Tie 2 was examined by immunoprecipitation followed by 
immunoblotting. Band intensities were quantified from scanned images of the blots using NIH 
Image (version 1.64). The relative ratio of the expressed amount of Src or MRP 1 was 
calculated as the ratio of Src or MRP 1 signal divided by the corresponding vinculin signal; 
each value was then normalized to the ratio obtained from control siRNA- transfected cells. 
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2.6 Measurement of secreted VEGF-A by HUVECs  
 
Two days after transfecion with either control or Src siRNA, HUVECs were 
suspended in medium containing 0.5% FBS, with or without 200 ng/ml Ang1, and seeded into 
12-well plates. Twenty-four hours later, culture medium was collected and the concentration of 
VEGF-A was quantified using the Quantikine® human VEGF-A ELISA kit according to the 
protocol provided by the manufacturer, to a sensitivity of 15 pg/ml VEGF. Culture medium not 
incubated with HUVECs was used as a background value. The values are expressed as mean 
concentration ± SD for triplicate wells. 
 
2.7 In vitro kinase assay 
  
In vitro kinase assay for Src was described previously [21]. In brief, cells were 
serum-starved for 2 h and were treated with either PP2 or 0.1% DMSO. One hour later, cells 
were either stimulated or left unstimulated with Ang1 for 10 min. Src was immunoprecipitated 
and kinase assay was performed by the use of acid-denatured enolase as a substrate. 
Incorporation of [-32P] ATP into enolase was examined by SDS-PAGE, followed by 
autoradiography. 
 
2.8 Statistical analysis  
 
Values are presented as mean length ± SD. Differences between two groups were 
analyzed using the Mann-Whitney’s U test. Differences were considered significant when the 
P value was less than 0.05. 
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3. Results 
 
3.1 Ang1 induces capillary morphogenesis by HUVECs cultured under both normoxic and 
hypoxic conditions 
 
First, we showed that Ang1 was able to induce capillary morphogenesis of 
HUVECs cultured under normoxic or hypoxic conditions, in a dose-dependent manner (Fig. 1). 
The morphological changes were similar under both conditions of oxygen tension; cells 
became elongated and fused in the presence of Ang1. 
 
3.2 Src is involved in Ang1-induced capillary morphogenesis by HUVECs 
 
In light of the reported role of Src family kinases in tube formation or capillary 
morphogenesis of endothelial cells [11, 12, 14, 20, 21], we next examined the effect of 
expression of Src on Ang1-induced capillary morphogenesis by using siRNA technique. The 
Src siRNA at 10 nM downregulated endogenous Src expression in HUVECs by ~75% 
compared to control siRNA-treated cells under both normoxic and hypoxic conditions, as 
assessed by densitometry (Fig. 2A). Fyn and Yes were not affected in the same experiments 
(data not shown). Downregulation of Src also potently inhibited Ang1-induced capillary 
morphogenesis by HUVECs cultured under both normoxic and hypoxic conditions (Fig. 2B), 
implicating Src in this process regardless of the ambient oxygen concentration. As shown in 
Fig. 2C, depletion of Src impaired capillary network formation by blocking normal cell 
spreading on a Matrigel surface and cell-cell contact via protrusions. 
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3.3 Src-dependent upregulation of VEGF-A is involved in Ang1-induced capillary 
morphogenesis 
 
We have previously shown that FGF-2-induced capillary morphogenesis by 
HUVECs requires endogenous VEGF-A-mediated signaling through VEGFR-1 [26]. In this 
report, the FGF-2-induced protrusion and extension of endothelial cells was inhibited in the 
presence of blocked VEGF-A signaling. In the fibroblast/endothelial cell co-culture model, 
VEGFR-2-mediated signaling via endogenous VEGF-A was required for Ang1-induced tube 
formation [27], and expression of VEGF-A was regulated through Src under normoxic and 
hypoxic conditions [28, 29]. These results suggest that endogenous VEGF-A may participate 
in Ang1-induced capillary morphogenesis. We therefore measured the secretion of VEGF-A 
by HUVECs cultured under both normoxic and hypoxic conditions. Cells transfected with 
either control or Src siRNA were cultured and culture medium was collected in the presence or 
absence of Ang1. Control siRNA- transfected cells showed significantly upregulated VEGF-A 
secretion following Ang1 treatment under both normoxic and hypoxic conditions, whereas Src 
siRNA transfection markedly downregulated the VEGF-A secretion by HUVECs (Fig. 3). This 
result indicated that Ang1 may stimulate the secretion of VEGF-A via Src family kinases. We 
next examined the effect of a blocking antibody against human VEGF-A, which inhibits the 
activity of human VEGF-A, but not of mouse VEGF-A [26], on Ang1-induced capillary 
morphogenesis. As shown in Fig. 4A, the VEGF-A blocking antibody significantly inhibited 
Ang1-induced capillary morphogenesis by HUVECs cultured under both normoxic and 
hypoxic conditions. Mouse VEGF-A (a ligand for both VEGFR-1 and -2), but not human 
PlGF-1 (a ligand only for VEGFR-1), restored this inhibition, suggesting that endogenous 
VEGF-mediated signaling through both VEGF-1 and VEGFR-2 was required for 
Ang1-induced capillary morphogenesis. We further examined the effect of exogenous 
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VEGF-A on Ang1-induced capillary morphogenesis by Src-depleted HUVECs. As shown in 
Fig. 4B, exogenous VEGF-A restored Ang1-induced capillary morphogenesis in the 
Src-depleted HUVECs, but had no effect on the Ang1-induced capillary morphogenesis by 
HUVECs transfected with control siRNA. Exogenous VEGF-A also induced cell spreading on 
Matrigel and protrusion followed by network formation (Fig. 4C). These results suggest that 
Ang1-induced capillary morphogenesis requires Src-dependent secretion of endogenous 
VEGF-A.  
 
3.4 Inhibition of Ang1-induced capillary morphogenesis in HUVECs by Src inhibitor PP2 is 
impaired under hypoxic culture conditions. 
 
We next examined the effect of Src family kinase inhibitor PP2 on Ang1-induced 
capillary morphogenesis by HUVECs, and showed a significant inhibition under normoxic 
conditions (Fig. 5A). However, under hypoxic conditions, the sensitivity of Ang1-induced 
capillary morphogenesis to PP2 treatment was decreased. The effect of PP2 on Src activity in 
HUVECs was then examined. As shown in Figure 5B, Ang1 activated Src in HUVECs 
cultured under both normoxic and hypoxic conditions. However, PP2 did not efficiently 
decrease the Src activity in HUVECs cultured under hypoxic conditions, suggesting that the 
effect of PP2 is impaired in hypoxic cells. Immunoblot analysis by using phospho-specific 
antibodies against Src showed that PP2 decreased the pY418 of Src in HUVECs cultured under 
normoxic conditions, but not in HUVECs cultured under hypoxic conditions (Fig. 5C). We 
also showed that an upstream regulator of Src, Tie 2 receptor tyrosine kinase was efficiently 
autophosphorylated in HUVECs cultured under both normoxic and hypoxic conditions in the 
presence of Ang1 (Fig. 5D), suggesting that the activation of Tie 2 was not affected by chronic 
hypoxia.  
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3.5 Impaired action of PP2 may be due to the upregulation of MRP 1 
 
Under hypoxic conditions, the multidrug resistance (MDR 1) gene is upregulated 
through HIF-1 [30]. The impaired effect of PP2 under these conditions in HUVECs may 
therefore be due to an elevated expression of MDR 1 protein. To address this, we treated 
HUVECs with a broad MDR inhibitor, verapamil, and then examined the effect of PP2. 
Verapamil at 0.2 M significantly restored the inhibitory action of PP2 on Ang1-induced 
capillary morphogenesis and Src activation (data not shown). Since expression of MDR 1 
protein was not altered by chronic hypoxia in HUVECs, we examined the expression of 
another transporter protein, MRP 1, the action of which is also inhibited by verapamil [31]. To 
compare the effect of acute and chronic hypoxia, some of the HUVECs cultured under 
normoxic conditions were transferred to hypoxic culture conditions for 8 h only. As shown in 
Fig. 6A, acute hypoxia markedly upregulated the HIF-1 expression which was extremely 
low in cells exposed to chronic hypoxia. Both acute and chronic hypoxic culture conditions 
strongly upregulated MRP 1 expression. These results indicate that upregulation of MRP 1 
may affect the intracellular concentration of PP2 in HUVECs cultured under hypoxic condition. 
We next examined the effect of depleting MRP 1 protein on PP2-mediated inhibition of 
Ang1-induced capillary morphogenesis. HUVECs cultured under chronic hypoxia were 
transfected with either MRP 1 siRNA or control siRNA and cultured for 2 days. MRP 1 siRNA 
downregulated the expression of MRP 1 (Fig. 6B), and in these cells, Ang1-induced Src 
activation was inhibited by PP2 (Fig. 6C). Furthermore, the sensitivity of capillary 
morphogenesis by HUVECs to PP2 was restored by the MRP 1 depletion (Figure 6D), 
suggesting that MRP 1 is important for the sensitivity of HUVECs to PP2 under hypoxic 
conditions. 
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4. Discussion 
 
4.1 Endogenous VEGF-A contributes to Ang1-induced capillary morphogenesis by HUVECs 
 
The signal transduction pathways that result in tube formation or capillary 
morphogenesis by Ang1-treated endothelial cells are poorly understood. The present study 
implicated Src as a likely downstream target of Tie 2, leading to capillary morphogenesis by 
endothelial cells. Downregulation of Src by siRNA inhibited cell spreading and protrusion of 
HUVECs on Matrigel, resulting in impaired capillary network formation, as well as decreasing 
the secretion of endogenous VEGF-A. Ang1-induced capillary morphogenesis was inhibited 
when endogenous VEGF-A was blocked. Addition of exogenous VEGF-A rescued 
Ang1-induced capillary morphogenesis by Src-depleted cells. Together, these results suggest 
that Ang1-induced secretion of VEGF-A through Src contributes significantly to capillary 
morphogenesis. Although a phosphoinositide 3-kinase (PI3-kinase) inhibitor, LY294002, 
modestly inhibit Ang1-induced capillary morphogenesis, but strongly inhibited the 
VEGF-A-induced capillary morphogenesis by HUVECs, PP2 weakly inhibited the capillary 
morphogenesis promoted by VEGF-A (S. Kanda, unpublished observation). In addition, 
VEGF-A had no further stimulatory effect on Ang1-induced capillary morphogenesis. Thus, 
Ang1-induced capillary morphogenesis may be partly attributed to VEGF-A-driven PI3-kinase 
activity. Depletion of Src expression impaired Ang1-induced cellular protrusion and extension 
of HUVECs, and similar defects were observed in PP2-treated cells (data not shown), 
suggesting that endogenous VEGF-A partially regulates cell shape and adhesion, which in turn 
requires turnover of focal adhesions and actin polymerization [32].  
 
4.2 The effect of PP2 was impaired in HUVECs chronically exposed to hypoxia. 
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Molecular targeting therapies in the future are expected to control advanced 
cancers in human. In particular, small-molecule protein kinase inhibitors have been tested 
widely clinical trials due to their easy accessibility (most are administered orally) and broad 
spectrum to a panel of protein kinases (targeting different kinds of kinases simultaneously). 
These reagents also inhibit both tumor progression and angiogenesis. In the present study, 
HUVECs cultured under hypoxic (1.5% O2) conditions were used to simulate the tumor 
environment in human to assess the inhibitory activity of PP2. PP2 inhibited Ang1-induced 
capillary morphogenesis in normoxic HUVECs, but had little effect in cells cultured under 
chronic hypoxic conditions. The protein MDR 1 is upregulated by hypoxia [30], and we 
observed that verapamil restored the inhibitory action of PP2 on both capillary morphogenesis 
and Src activity of HUVECs cultured under hypoxic conditions, suggesting that multidrug 
resistance may be involved in the attenuated activity of PP2. Although MDR 1 expression was 
not upregulated under hypoxic conditions, another transporter MRP 1 was upregulated, and 
downregulation of MRP 1 in hypoxic HUVECs restored the sensitivity to PP2. These results 
therefore suggest that small molecule protein kinase inhibitors may be exported via the 
ATP-binding cassette (ABC) family of membrane ATPase transporters [33]. Interestingly, the 
action of a protein tyrosine kinase inhibitor of the 2-phenylaminopyrimidine series, imatinib, is 
impaired in imatinib-resistant leukemia cells [34] and is exported via MDR [35]. In addition, 
low expression of MRP 1 was a significant predictive factor of imatinib sensitivity in chronic 
myeloid leukemia [36]. Based on these findings and the results of this study, testing of small 
molecule protein kinase inhibitors in patients with advanced cancers should consider the 
activity of ABC membrane transporters.  
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Figure legends 
 
Fig. 1. Ang1 induces capillary morphogenesis by HUVECs cultured under both normoxic and 
hypoxic conditions in a dose-dependent manner. HUVECs cultured under normoxic or 
hypoxic (1.5% oxygen in N2) for more than 7 days were harvested, suspended in culture 
medium containing 0.5% FBS, and cultured onto growth factor-reduced Matrigel in the 
presence or absence of Ang1 at indicated concentrations for 24 h. Photographs were taken 
under a phase-contrast microscope. Capillary length of cells without any treatment was set to 
1.0. Values are expressed as means ± SD of three images. Bar, 20 m. Reproducible results 
were obtained from two independent experiments.  
 
Fig. 2. Downregulation of Src inhibits Ang1-induced capillary morphogenesis by HUVECs 
cultured under both normoxic and hypoxic conditions. (A) Src siRNA at 10 nM efficiently 
downregulated Src in HUVECs cultured under both normoxic and hypoxic conditions. 
HUVECs were transfected with either control siRNA or Src siRNA at 10 nM and cultured for 
48 h. Cells were harvested and equal number of cells were lysed, run on SDS-PAGE, and Src 
expression was examined by immunoblotting. Vinculin expression was measured as a loading 
control. The remaining cells were used for the capillary morphogenesis assay as described 
below. (B) Downregulation of Src by siRNA at 10 nM inhibited Ang1-induced capillary 
morphogenesis by HUVECs cultured under both normoxic and hypoxic conditions. Cells 
transfected with indicated siRNA were suspended in EBM-2 containing 0.5% FBS and seeded 
onto Matrigel. Ang1 (200 ng/ml) was added to the indicated cells. Capillary morphogenesis 
was estimated as described in the legend of Fig. 1. Values are expressed as means ± SD of three 
images. Bar, 100 m. Reproducible results were obtained from two independent experiments. 
(C) Downregulation of Src by siRNA at 10 nM inhibited Ang1-induced cell spreading on 
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Matrigel and protrusion. Cells transfected with either control siRNA or Src siRNA were seeded 
onto a Matrigel surface. Micrographs were taken consecutively at indicated periods.  
 
Fig. 3. Effect of Src siRNA on VEGF-A secretion by HUVECs cultured under normoxic and 
hypoxic conditions. HUVECs treated with the indicated siRNA at 10 nM were cultured for 2 
days under either normoxic or hypoxic conditions and then cells were harvested and seeded 
onto 24-well plates. Cells in EBM-2 medium containing 0.5% FBS supplemented with or 
without Ang1 (200 ng/ml) were cultured for 24 h and conditioned medium was collected. 
VEGF-A concentration was measured by Quantikine ELISA kit. VEGF-A content was 
normalized to cell number. Values are expressed as means ± SD of triplicate wells. Similar 
results were obtained from two independent experiments. 
 
Fig. 4. (A) Blockage of endogenous VEGF-A by blocking antibody inhibits Ang1-induced 
capillary morphogenesis by HUVECs under both normoxic and hypoxic conditions. HUVECs 
were suspended in EBM-2 containing 0.5% FBS and seeded onto Matrigel. Normal goat IgG or 
anti-VEGF-A blocking antibody at a concentration of 2.5 g/ml, Ang1 (200 ng/ml), mouse 
VEGF-A (20 ng/ml), and human PlGF-1 (50 ng/ml) was added to the cells as indicated. 
Capillary morphogenesis was estimated as described in the legend of Figure 1. Values are 
expressed as means ± SD of three images. Bar, 100 m. Reproducible results were obtained 
from two independent experiments. (B) Addition of exogenous VEGF-A restored 
Ang1-induced capillary morphogenesis by HUVECs transfected with Src siRNA (10 nM). 
HUVECs transfected with the indicated siRNA were cultured for 2 days under either normoxic 
or hypoxic conditions and then cells were harvested and seeded onto Matrigel and cultured in 
the presence or absence of indicated samples. Values are expressed as means ± SD of three 
images. Reproducible results were obtained from two independent experiments. (C) Addition 
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of exogenous VEGF-A restored Ang1-induced cell spreading on Matrigel and protrusion by 
HUVECs transfected with Src siRNA (10 nM). Cells transfected with Src siRNA were seeded 
onto the surface of Matrigel and cultured in the presence of indicated samples. Micrographs 
were taken consecutively at indicated periods. Reproducible results were obtained from two 
independent experiments.  
 
Fig. 5. PP2 inhibits Ang1-induced capillary morphogenesis of HUVECs cultured under 
normoxic conditions, but not under hypoxic conditions. (A) HUVECs were suspended in 
EBM-2 containing 0.5% FBS and seeded onto Matrigel. Indicated samples were added to the 
cells and culture was continued for 24 h. Values are expressed as means ± SD of three images. 
Bar, 100 m. Reproducible results were obtained from three independent experiments. (B) PP2 
failed to inhibit Ang1-induced Src activation in HUVECs cultured under hypoxic condition. 
HUVECs were cultured in 6 cm dishes and incubated with serum-free medium with or without 
PP2 (1 M) for 2 h, then either stimulated or left unstimulated with 200 ng/ml of Ang1 for 10 
min. Src was immunoprecipitated from the 90% of the cell lysate and in vitro kinase assay was 
performed. The remaining 10% of each lysate was assessed for the loaded amount of protein by 
immunoblotting. Reproducible results were obtained from two independent experiments. (C) 
PP2 failed to inhibit Ang1-induced autophosphorylation of Src in HUVECs cultured under 
hypoxic condition. HUVECs were cultured in 6-cm dishes and incubated with serum-free 
medium with or without PP2 (1 M) for 2 h, then either stimulated or left unstimulated with 
200 ng/ml of Ang1 for 10 min. Src was immunoprecipitated and site-specific phosphorylation 
was examined by immunoblotting. Reproducible results were obtained from two independent 
experiments. (D) Tyrosine phosphorylation of Tie 2 was not affected by chronic hypoxia. 
HUVECs grown in 10-cm dishes were serum-starved for 2 h and were either stimulated or left 
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unstimulated with 200 ng/ml of Ang1 for 10 min. Tie 2 was immunoprecipitated and 
autophosphorylation was examined by immunoblotting.  
 
Fig. 6. Impaired activity of PP2 in HUVECs cultured under hypoxic condition may be due to 
an increase in MRP 1 protein. (A) Expression of MRP 1 was upregulated in HUVECs cultured 
under hypoxic conditions. Cells cultured in 24-well plates were lysed and equal cell numbers 
were resolved by SDS-PAGE, followed by immunoblotting. Expression of vinculin was 
examined as a loading control. Reproducible results were obtained from two independent 
experiments. (B) Downregulation of MRP 1 by siRNA. HUVECs cultured under hypoxic 
conditions were transfected with either control siRNA or MRP 1 siRNA at 50 nM and two days 
later, cells were harvested, counted and proteins from 4 x 104 cells were separated by 
SDS-PAGE, followed by immunoblotting. (C) Downregulation of MRP 1 restored the 
inhibitory action of PP2 on Ang1-induced Src activation. Hypoxic HUVECs transfected with 
either control siRNA or MRP 1 siRNA at 50 nM were either treated or left untreated with Ang1 
at 200 ng/ml for 8 min in the presence or absence of PP2 as described in the legend of Fig. 5 B. 
Src was immunoprecipitated followed by immunoblotting to examine the activation of Src. (D) 
The remaining HUVECs prepared in (B) were examined for Ang1-induced capillary 
morphogenesis in the presence or absence of PP2. Values are expressed as means ± SD of three 
images. Bar, 100 m. Reproducible results were obtained from two independent experiments. 
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